Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Celecoxib/tramadol - ESTEVE

Next Previous
Drug Profile

Celecoxib/tramadol - ESTEVE

Alternative Names: E-58425; MR308; Seglentis; Tramadol/Celecoxib

Latest Information Update: 02 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ESTEVE
  • Developer ESTEVE; Mundipharma GmbH
  • Class Analgesics; Anti-inflammatories; Cyclohexanols; Dimethylamines; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Opioid analgesics; Phenyl ethers; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Adrenergic uptake inhibitors; Cyclo-oxygenase 2 inhibitors; Opioid mu receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Acute pain
  • Discontinued Dental pain; Pain

Most Recent Events

  • 19 Jul 2022 Efficacy and adverse events data from a phase III trial in Acute pain released by Kowa Pharmaceuticals America (NCT03108482)
  • 20 Oct 2021 Registered for Acute pain in USA (PO)
  • 20 Oct 2021 US FDA approves New Drug Application (NDA) for the treatment of Acute pain in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top